Aim: Up-regulation of soluble CD40 ligand (sCD40L) and of monocyte chemoattractant protein-1 (MCP-1) has been found in diabetes and in patients with acute cerebral ischemia. We asked whether (i) the two molecules are similarly upregulated among non-lacunar and lacunar diabetic strokes and (ii) sCD40L and/or MCP-1 predict the risk of cardiovascular events in this setting. Methods: Ninety patients with type 2 diabetes mellitus presenting with an acute ischemic stroke (compared with 45 control subjects) were evaluated on admission and up to 36 months (median 24 months) after the event. 
Cytokines and cytokine-inducible inflammatory molecules are regarded as predictive markers of cardiovascular events 7) . It is known that CD40 signaling mediates many inflammatory responses in atherosclerosis 8) . Enhanced CD40 ligand (CD40L) release is associated with thromboxane-dependent platelet activation in type 2 diabetes 9) . Activated platelets induce monocyte chemoattractant protein-1 (MCP-1) release from endothelial cells in a CD40L-dependent manner 10) . MCP-1 is a chemokine responsible for the recruitment of monocytes to inflammation sites and its expression level is directly related to the extent of atherosclerosis and macrophage infiltration into the atherosclerotic lesion 11) . MCP-1 levels are increased in type 2 diabetes and are associated with increased risk of cardiovascular mortality 12) . Upregulation of soluble
Introduction
Diabetes is a major risk factor for stroke 1, 2) and is associated with an increase in overall stroke mortality attributable to higher-than-optimum blood glucose concentration 3) . Admitted patients with diabetes mellitus show a higher prevalence of lacunar stroke subtype than non-diabetics 4) . Whether lacunar strokes are associated with a different outcome vs non-lacunar strokes in diabetics is controversial 5, 6) . CD40L (sCD40L) and MCP-1 has been found in patients with acute cerebral ischemia, even though only 22% of patients with stroke or transient ischemic attack were diabetics 13) . We asked whether, in a cohort of diabetic subjects with acute ischemic stroke (i) the two molecules are similarly up-regulated among non-lacunar and lacunar strokes and (ii) CD40L and/or MCP-1 may predict the risk of cardiovascular events in ischemic stroke.
Subjects
Between November 2002 and February 2006, we evaluated a cohort of 90 patients with type 2 diabetes mellitus, defined according to the World Health Organization diagnostic criteria for diabetes 14) presenting with an acute ischemic stroke, as diagnosed on the basis of neurological signs and symptoms and compatible CT findings, at the Department of Internal Medicine of Palermo University Hospital within 72 hours after the onset of symptoms. Patients with symptoms lasting for 72 hours on admission were excluded from the study. Further exclusion criteria were acute and chronic inflammatory diseases, autoimmune diseases or malignancies, acute coronary syndromes, intracerebral haemorrhage, and treatment with hormonal replacement therapy, steroids, and nonsteroidal anti-inflammatory drugs. A detailed history was obtained (Table 1) .
Standard diagnostic tests included cranial computed tomography to exclude intracerebral haemorrhage, duplex sonography to detect or exclude significant stenosis of carotid arteries, and echocardiography to exclude the presence of an intracardiac thrombus.
Acute cerebral ischemias were classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria 15, 16) . Severity of stroke was evaluated by the Scandinavian Stroke Scale (SSS) score on 17) . SSS is an acute stroke assessment scale based on scored assessments of: level of consciousness, eye movement, arm motor power, hand motor power, leg motor power, orientation, speech, facial palsy, and gait. Forty-five subjects (26 males and 19 females, Table 1 ) were also recruited for the study as a control group. They were recruited from our vascular event prevention clinic and they were free of any previous vascular event. Controls were matched for sex and age with stroke patients. All patients gave written informed consent. The study was approved by the local ethics committee.
Patients were re-evaluated in our clinic every three months up to 36 months after the event (median follow-up 32 months; range 4 − 36) or when they experienced cardiovascular events (myocardial infarction, angina, stroke, transient ischemic attack, critical limb ischemia, need for percutaneous revascularization procedures or coronary artery by-pass).
Methods

Biochemical Measurements
Blood samples, collected within 72 hours of the ischemic event, were processed according to the recent recommendations regarding the appropriate specimen and preparation for laboratory evaluation of sCD40L 18, 19) . Thus, blood samples were anticoagulated in Na citrate 3.8% (1:9 v:v), centrifuged at 2,000 g for 10 minutes at 4 . Supernatants were collected. Plasma was stored at 80 until analysis. Plasma CD40L and MCP-1 levels were measured by enzymelinked immunosorbent assay (R&D Systems, Minneapolis, Minnesota).
Statistical Analysis
Statistical analysis was performed by chi-square statistics, Pearson's correlation coefficient t test for independent samples and by one-way analysis of variance with Bonferroni adjustment to assess differences among groups. When necessary, appropriate nonparametric tests were used (Spearman correlation coefficient and Mann-Whitney U test). Because the distribution of sCD40L and MCP-1 was skewed (ShapiroWilk test) the concentration of these variables was also analyzed statistically by quartiles. Multiple linear regression analysis was performed to further quantify the relationship between MCP-1 (divided into quartiles) and the possible explanatory factor. Specifically, the dependent variable, MCP-1, was regressed for sCD40L (divided into quartiles), age, SSS score, sex, TOAST group, HbA1c, arterial blood pressure, total cholesterol, BMI, diabetes duration, and previous vas- (Fig. 1) .
No significant differences in plasma CD40L or MCP-1 levels among different TOAST groups (p 0.486 and p 0.378, respectively, Among all patients, plasma MCP-1 directly correlated with sCD40L (Rho 0.69, p 0.0001). Because the distribution of sCD40L (Shapiro-Wilk W 0.75815, p 0.00001) and MCP-1 (Shapiro-Wilk W 0.87251, p 0.0001) was skewed, the concentration of these variables was also analyzed statistically by quartiles.
Thus, multiple-linear regression analysis was performed to further quantify the relationship between plasma sCD40L and MCP-1 and the other possible explanatory factors. Multiple regression analysis indicated that only higher sCD40L quartiles (b 0.70, SE 0.08; p 0.0001) and higher age (b 0.21, SE 0.08; p 0.02) were associated with higher MCP-1 quartiles, independently of SSS score, sex, TOAST group, HbA1c, diabetes duration, body mass index, systolic and diastolic blood pressure, total cholesterol, and previous vascular events. In fact, 17 out of 24 patients (71%) with MCP-1 in the upper quartile showed sCD40L in the upper quartile.
At discharge from the stroke unit, the SSS score showed a significantly improvement in all included patients (36.7 10.2 to 44.8 10.6, t 12.73, median change 29%, p 0.0001). Nevertheless, MCP-1, sCD40L plasma levels, and the other risk factors did not show any significant correlation with SSS improvement.
Median follow-up was 24 months (12 to 36 months). No patient was lost to follow-up. Three patients died of causes unrelated to vascular events (censored data). Forty-three (48%) patients experienced vascular events (1 fatal and 4 nonfatal myocardial infarctions, 9 episodes of unstable angina, 7 strokes, 15 transient ischaemic attacks, 7 critical limb ischemia). No significant difference was observed in the rate of vascular events among patients with lacunar vs non-lacunar stroke ( Table 2) Univariate and multivariate analyses were performed by the Cox proportional hazard model: the first step was performed by the log rank test, and the covariates found to be associated were included in the Cox regression model (Fig. 2) . Of the parameters listed in Table 2 , only high sCD40L levels were entered in the Cox proportional hazard model. In fact, the presence of higher sCD40L values had an independent prognostic value in predicting the recurrence of vascular events (hazard ratio 2.6, 95% confidence limits: 1.9 − 3.6, p 0.001). In particular, 31 (72%) out LAA large-artery atherosclerosis (non-lacunar stroke), CE cardioembolic (nonlacunar stroke), SAO small artery occlusion (lacunar stroke). Error bars represent minimum and maximum values, the heavy horizontal rules indicate median values, and the ends of the boxes indicate interquartile range. Mann-Whitney U test of 43 patients who experienced an event during follow-up had CD40L and MCP-1 in the third and fourth quartiles.
Discussion
Type 2 diabetes is characterized by persistent platelet activation 20) , responsible for increased plasma levels of CD40L in this setting 9) . CD40L released from platelets induces inflammatory responses in the endothelium 21) . Activated platelets stimulate MCP-1 production from endothelial cells through enhanced CD40L shedding 10) and this seems particularly relevant in type 2 diabetes 12, 22) . MCP-1 plays an important role in the early phase of atherosclerosis by initiating monocyte recruitment to the vessel wall 23) ; thus, platelet-derived CD40L can trigger the recruitment of monocytes or promote their differentiation into macrophages 21) , inducing MCP-1 release from the endothelium. Upregulation of MCP-1 and sCD40L has been found in patients with acute cerebral ischemia 13) . Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure 10) . In patients with acute coronary syndromes 24) , as well as in type 2 diabetes 12) , an elevated baseline level of MCP-1 is associated with an increased risk for cardiovascular death.
The evidence for a role of sCD40L in cardiovascular disease is even greater, suggesting that CD40L levels are a prominent candidate for early detection in cardiac disease 25, 26) . Activation of the CD40-CD40L dyad has been observed in atherosclerosis-related diseases 19) and CD40L levels may predict cardiovascular risk in women 27) . Acute cerebral ischemia is associated with persistent thromboxane-dependent platelet activation in vivo 5) . Up-regulation of CD40-CD40L has been also shown in patients with acute cerebral ischemia 13) and high levels of sCD40L may predict the risk of cardiovascular events both in high-risk plaques 28) and in asymptomatic low-grade carotid stenosis 29) . This study demonstrates for the first time that early elevation of plasma CD40L and MCP-1 after an acute stroke is associated with long-term risk of nonfatal vascular events in a large group of patients with diabetes and acute stroke. On multiple-linear regression analysis, all patients with MCP-1 levels in the third/fourth quartiles showed sCD40L values in the two highest quartiles. Moreover, we demonstrated the potential prognostic value of an elevated CD40L level in stroke patients during 2 years of follow-up, thus suggesting that CD40L shedding acting at the interface between endothelial cells and platelets, and thereby triggering both inflammation and platelet activation, is an early event upstream of vascular events. These findings strongly suggest that enhanced plateletderived mediators of the inflammatory response may predict the risk of cardiovascular events after stroke.
The age-standardized incidence rates for the European population (per 100 000) regarding ischemic stroke subtypes were as follows: cardioembolism, 30.2; small-artery occlusion, 25.8; and large-artery atherosclerosis, 15.3. Two years after onset, patients in the small-artery occlusion subgroup were 3 times more likely to be alive than those with cardioembolism 15) . We found that sCD40L and MCP-1 are similarly up-regulated among nonlacunar and lacunar strokes, in agreement with a recent meta-analysis showing a similar risk of cardiac outcome in longer term surveillance between the two subtypes 6) .
In conclusion, up-regulation of inflammatory molecules, such as CD40L and MCP-1, is involved in the advanced stage of diabetic cerebro-vascular disease. Elevated CD40L levels are associated with an increased risk of recurrence of cardiovascular events. Statins are able to downregulate both soluble MCP-1 and CD40L 30, 31) and a number of additional drugs, including glitazones, antioxidant and antiplatelets, have been shown to favorably modulate sCD40L 32) . Thus, both CD40L and MCP-1 are attractive as surrogate biomarkers and merit further study as potential therapeutic targets in diabetic acute cerebral ischemia.
